Corcept Therapeutics is trading 4.71% up at $82.95 in pre-market on November 5, with biotech stocks up 2.08%. - The company reported Q3 revenue of $340.5 million on November 3, up 64%, and reiterated 2026 revenue guidance of $1.1–$1.2 billion. - Shares fell after the earnings beat, with unchanged guidance cited as a concern. The stock closed at $79.22 on November 4; no new company announcement was identified for November 5.